AI-generated summary
The authors report a randomized, double-blind trial in which patients on methadone maintenance received transcranial photobiomodulation or a sham treatment. Anxiety, depression and opioid craving scores were reduced more in the active group than in the sham group, with improvements reported at one and three months. The sample was small and predominantly male.
- Who or what was studied
- Substance-dependent patients undergoing methadone maintenance treatment, 91.4% male
- Wavelengths
- 810 nm
- Limits stated in the abstract
- The abstract reports a predominantly male sample and does not state a study-specific limitation beyond this.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmcpsychiatry.biomedcentral.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
- Energy density (fluence)
- 60 J/cm2
- Power density (irradiance)
- 250 mW/cm2
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Depression, Anxiety, Photobiomodulation, Photobiomodulation therapy, Trial registration, Sham, Adenosine triphosphate. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.